
0:00
1:07:22
Moderator: SABCS Co-director Kent Osborne, MD, director of the Dan L Duncan Cancer Center at Baylor College of Medicine
- T-DM1 Improved Overall Survival for Heavily Pretreated Patients With HER2-positive Breast Cancer;
- Phase III BELLE-2 Trial Meets Primary Endpoint of Progression-free Survival;
- No Significant Difference in Recurrence Rates Among Women With DCIS Taking Anastrozole or Tamoxifen; and
- DCIS Patients Receiving Anastrozole Reported Symptoms Different From Those Receiving Tamoxifen.
Altri episodi di "AACR Scientific Podcasts"



Non perdere nemmeno un episodio di “AACR Scientific Podcasts”. Iscriviti all'app gratuita GetPodcast.



